Since our inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business and scientific planning, conducting discovery and research and development activities, establishing, maintaining, and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials, establishing arrangements with third parties for the manufacture of our product candidates and component materials, engaging in collaboration activities, and providing general and administrative support for these operations
The FDA is tightening enforcement
Bao, H., Ge, Y., Zhuang, S., Dworkin, L
Our NAMs are designed to prevent the activation of TSHR even in the presence of excess amounts of TSHR activating autoantibodies, thus potentially providing protection for patients with high serum antibody levels and for patients with polyclonal activating antibodies
Two prior authorization policies required at least two comorbidities and 70% of policies specified the conditions
Escherichia coli, Proteus mirabilis, Acinetobacter lwoffii, Bacillus, Penicillium, and Rhizopus are among the additional microorganisms